Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China have?
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China has 42 citations in the OpenAlex counts ScholarIQ stores.
When was Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China published?
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China has 2022 year in the ScholarIQ index.
What is the open-access status of Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China?
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China has hybrid oa status in the ScholarIQ index.
What is the DOI of Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China?
The DOI for Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China is on the source record.
What is the PMID of Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China?
The PMID for Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China is on the source record.
What is the OpenAlex record for Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China?
The OpenAlex for Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China is on the source record.